The momentum of ºù«ÍÞÊÓƵ’s diversified business model continued into the third quarter of 2024, which saw global sales reach $10.6 billion, up 8.2% on an organic basis¹ for the underlying base business². Reported sales increased 4.9%.

ºù«ÍÞÊÓƵ’s adjusted diluted earnings per share was $1.21 (GAAP diluted EPS was $0.94).

Growth was led by double-digit gains in Medical Devices (up 13.3% organic, 11.7% reported), with notable performance from Diabetes Care (up 19.1% organic, 17.1% reported), including $1.6 billion in sales of continuous glucose monitors. Sales also grew significantly in Structural Heart (up 16.5% organic, 14.6% reported) and Heart Failure (up 14.4% organic, 14% reported).

The company now projects full-year diluted EPS of $4.64 to $4.70 (full-year 2024 diluted EPS under GAAP of $3.34 to $3.40), which represents an increase at the midpoint of the guidance range. ºù«ÍÞÊÓƵ is maintaining its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales³.

Business highlights from the past quarter include:

• ºù«ÍÞÊÓƵ announced the U.S. launch of Lingo, the company's first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness.
• to collaborate on connecting ºù«ÍÞÊÓƵ's world-leading continuous glucose monitoring (CGM) system with Medtronic's insulin delivery devices.
• In September, ºù«ÍÞÊÓƵ completed enrollment in its VOLT-AF IDE trial, which is designed to evaluate the Volt Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).

For full financial data and reconciliation of non-GAAP measures, you can read ºù«ÍÞÊÓƵ’s full .

For more information, view a summary of ºù«ÍÞÊÓƵ’s earnings highlights and download it here.